Labcorp 3Q 2026: Revenue $3.81B, EPS $3.22— 10-Q Summary

What happened

Labcorp reported third-quarter 2026 revenue of $3.81 billion, up 6.9% from a year earlier. Net income rose 0.7% to $262.8 million and diluted earnings per share increased 3.2% to $3.22. Growth came from organic gains and acquisitions, net of divestitures.

Confirmed

Global impact / market context

Revenue grew faster than profit, so each sales dollar kept less profit than before. Cost of revenues still consumed 70.9% of revenue, a slight improvement. That gap means investors should watch whether recent acquisitions and steady pricing turn into stronger profit growth rather than just a larger revenue base.

Analyst inference

Diagnostics revenue rose 6.5% on 4.8% more test requisitions, which means volume and price both helped. Business Laboratory Services grew 8.5%, led by 9.6% organic growth, with operating efficiencies supporting profit per sale. Labcorp also announced planned acquisitions in laboratory testing, prenatal health and specialty drug testing, subject to closing conditions.

Analyst inference

What to watch

1. Cost of revenues fell to 70.9% of revenue from 71.2%, which means Labcorp kept a little more of each sales dollar after direct testing costs. Watch whether this modest improvement continues as revenue grows. Confirmed
2. Labcorp plans acquisitions in laboratory testing, prenatal health and specialty drug testing. These deals remain subject to closing conditions, so watch whether they complete and how the acquired businesses change revenue and costs. Proposed
3. Net income rose only 0.7% while revenue rose 6.9%, so profit growth lagged sales growth. Watch whether acquisitions, organic volume and operating efficiencies narrow that gap or add integration costs that keep profit per sale under pressure. Analyst inference

Evidence

• Original source link unavailable